The U.S. Food and Drug Administration (FDA) has approved Cardamyst™ (etripamil) nasal spray to treat adults with paroxysmal supraventricular tachycardia (PSVT). This rapid-acting, self-adminstered treatment option is expected to be available in retail pharmacies in the U.S. starting in early 2026.

The agency handed down approval after results from the Phase 3 RAPID trial found that participants using Cardamyst were "two times as likely to convert symptomatic PSVT to sinus rhythm and did so three times faster" when compared to participants assigned a placebo. Learn more.

Clinical Topics: Arrhythmias and Clinical EP, SCD/Ventricular Arrhythmias

Keywords: United States Food and Drug Administration, Nasal Sprays, Tachycardia, Ventricular, ACC Advocacy